Holocene Advisors LP Cuts Holdings in Soleno Therapeutics, Inc. $SLNO

Holocene Advisors LP lowered its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 13.5% during the third quarter, Holdings Channel.com reports. The firm owned 997,069 shares of the company’s stock after selling 155,979 shares during the quarter. Holocene Advisors LP’s holdings in Soleno Therapeutics were worth $67,402,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Raymond James Financial Inc. acquired a new position in shares of Soleno Therapeutics during the second quarter worth about $25,000. Aster Capital Management DIFC Ltd acquired a new stake in Soleno Therapeutics in the third quarter valued at approximately $37,000. Osaic Holdings Inc. raised its holdings in Soleno Therapeutics by 97.7% in the second quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock valued at $72,000 after acquiring an additional 423 shares in the last quarter. KBC Group NV purchased a new position in Soleno Therapeutics in the second quarter worth approximately $77,000. Finally, Quantbot Technologies LP acquired a new position in Soleno Therapeutics during the 3rd quarter worth approximately $67,000. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Stock Performance

Shares of Soleno Therapeutics stock opened at $33.39 on Tuesday. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. Soleno Therapeutics, Inc. has a 52 week low of $32.63 and a 52 week high of $90.32. The firm’s 50 day moving average is $40.50 and its two-hundred day moving average is $50.69. The firm has a market capitalization of $1.72 billion, a P/E ratio of 145.18 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to analysts’ expectations of $88.55 million. Research analysts forecast that Soleno Therapeutics, Inc. will post -3.72 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on SLNO shares. TD Cowen dropped their price objective on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a research note on Tuesday, January 13th. Wolfe Research set a $60.00 target price on Soleno Therapeutics in a report on Monday, January 12th. Wall Street Zen upgraded Soleno Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Zacks Research downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Soleno Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.85.

Key Stories Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Analysts still show support: SLNO retains a consensus rating of “Moderate Buy,” which could limit downside if fundamentals or clinical updates improve. Analyst Consensus Article
• Neutral Sentiment: Market visibility: coverage notes that SLNO has gained attention in the Nasdaq composite today — this can amplify moves (both up and down) as momentum traders respond. Market Attention Article
• Negative Sentiment: Class‑action litigation: a securities class action has been filed alleging Soleno concealed drug safety risks and that the company’s November 2025 DCCR/VYKAT™ XR disclosures harmed investors. That complaint (and related press) is the core negative catalyst investors cite. Hagens Berman Article
• Negative Sentiment: Multiple law firms soliciting plaintiffs: numerous firms (Rosen, Glancy Prongay Wolke & Rotter, Faruqi & Faruqi, Levi & Korsinsky, Robbins Geller, Kaplan Fox, Schall, DJS, etc.) have issued notices reminding investors of a May 5, 2026 lead‑plaintiff deadline and encouraging filings — increasing media attention and legal risk premium on the stock. Rosen Notice
• Negative Sentiment: Put buying surge: unusually large options activity — ~5,314 put contracts traded (≈109% above typical put volume) — signals increased bearish positioning and hedging demand, which can amplify downward pressure on the share price. (Intraday options flow reported by market data.)

Soleno Therapeutics Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.